Patent SG-11201907358R-A (SG)
Title: Intrasite administration and dosing methods and pharmaceuticals for use therein
Inventor: HOLEKAMP TERRENCE
IPC: A61L27/00
Filed: 2018-02-08
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT 0111111010 0111 °nolo DID IH mo IH Imio oimIE (10) International Publication Number WO 2018/148455 Al (51) International Patent Classification: A61L 27/00 (2006.01) A61L 15/00 (2006.01) A61L 26/00 (2006.01) (21) International Application Number: PCT/US2018/017486 (22) International Filing Date: 08 February 2018 (08.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/456,639 08 February 2017 (08.02.2017) US 62/456,642 08 February 2017 (08.02.2017) US (71) Applicant: HKL MEDICAL, LLC [US/US]; 1965 Broad- way, Apt. 22AB, New York, NY 10023 (US). (72) Inventors: HOLEKAMP, Terrence, Fletcher; 1529 Grandview Place, East Seattle, WA 98112 (US). KEL- LY, Michael, Patrick; 4367 McPherson Avenue, Saint Louis, MO 63108 (US). LENKE, Lawrence, Gerard; 1965 Broadway, Apt. 22AB, New York, NY 10023 (US). (74) Agent: GIORDANO, David et al.; Giordano Law LLC, 1 Boston Place, Suite 2600, Boston, MA 02108 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN (57) : A new method of targeted intrasite drug administration to wounds offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing intrasite medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large intrasite doses increase risk of toxicity from impurities allowed in drugs given by other routes. Pharmacodynamic parameters make certain drugs advantageous as intrasite agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an intrasite medication. Other drugs, including but not limited to rifaximin, possess similar pharmacodynamics and may be useful intrasite pharmaceuticals, delivered alone or in combination with other drugs, carriers, or materials. All of these attributes are advantages over traditional administration methods.